Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

3.0K
3.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.7K
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

19.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality of life and mental health in pediatric patients with low-grade CNS tumors treated with surgery alone.

Journal of neurosurgery. Pediatrics·2026
Same author

Suicidal Ideation Experienced by Long-Term Survivors of Blood or Marrow Transplantation: A Blood or Marrow Transplant Survivor Study Report.

Transplantation and cellular therapy·2026
Same author

Adherence-enhancing intervention and relapse in childhood acute lymphoblastic leukemia: results from the Children's Oncology Group randomized trial ACCL1033.

Leukemia·2026
Same author

Perioperative Ostomy Care and Education Experiences by Patient and Caregiver Health Literacy.

The Journal of surgical research·2026
Same author

Total body irradiation and smoking interact to increase lung cancer risk after blood or marrow transplantation.

Blood advances·2026
Same author

Geographic Diversity of Articles Published over Two Decades in Leading Medical Journals.

Journal of general internal medicine·2026

Related Experiment Video

Updated: Mar 26, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

10.1K

Ototoxicity and cancer therapy.

Wendy Landier1

  • 1Department of Pediatric Hematology/Oncology, Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, Alabama.

Cancer
|February 10, 2016
PubMed
Summary

Ototoxicity, a side effect of cancer treatments like chemotherapy and radiation, impacts hearing in 4-90% of patients. Early detection and intervention are crucial for managing hearing loss and improving patient outcomes.

Keywords:
antineoplastic therapygenetic predispositiongrading scalesmanagement of hearing lossotoprotectionototoxicity

More Related Videos

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields
08:14

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Published on: May 4, 2017

15.9K
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

18.7K

Related Experiment Videos

Last Updated: Mar 26, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

10.1K
Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields
08:14

Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields TTFields

Published on: May 4, 2017

15.9K
The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration
12:21

The Mouse Round-window Approach for Ototoxic Agent Delivery: A Rapid and Reliable Technique for Inducing Cochlear Cell Degeneration

Published on: November 26, 2015

18.7K

Area of Science:

  • Oto-oncology
  • Clinical audiology
  • Pharmacology

Background:

  • Ototoxicity is a significant adverse effect of various cancer therapies, including platinum chemotherapy, radiation, and certain supportive care medications.
  • The prevalence of ototoxicity varies widely (4-90%) based on patient age, treatment specifics, and cumulative dosage.
  • The impact of ototoxicity is substantial, particularly affecting psychosocial outcomes and health in young children.

Purpose of the Study:

  • To review the current understanding of ototoxicity in cancer patients.
  • To highlight the variability in prevalence and severity, suggesting a role for genetic susceptibility.
  • To discuss the status of otoprotective agent development and the importance of prospective monitoring.

Main Methods:

  • Literature review of studies on ototoxicity associated with antineoplastic therapies.
  • Analysis of factors influencing ototoxicity prevalence and severity.
  • Discussion of current research on otoprotective agents and monitoring strategies.

Main Results:

  • Ototoxicity is linked to platinum chemotherapy, radiation, aminoglycosides, and loop diuretics.
  • Significant interindividual variability in ototoxicity suggests genetic risk factors.
  • No US Food and Drug Administration-approved otoprotectants are currently available.

Conclusions:

  • Prospective monitoring for ototoxicity is essential for early detection and intervention.
  • Monitoring facilitates auditory rehabilitation and ameliorates hearing loss consequences.
  • Further research into otoprotective strategies is needed to mitigate treatment-related hearing damage.